Navigation Links
Histogen to Present Preliminary Hair Regrowth Clinical Results at Stem Cell Summit
Date:2/16/2009

Company will Share Sneak Peek at Safety and Efficacy Results from In Progress Clinical Trial

New York (PRWEB) February 16, 2009 -- Dr. Gail Naughton, CEO of Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts grown under embryonic conditions, will address attendees tomorrow at the 4th Annual Stem Cell Summit in New York. Dr. Naughton will be presenting preliminary mid-trial results from Histogen's first human clinical evaluation of ReGenicaTM for hair regrowth.

The primary objective of this double-blind, placebo-controlled, randomized study is to evaluate safety in the clinical application of the ReGenica product for hair regrowth. Histogen is also examining product efficacy as a secondary objective, specifically looking at the same end-points the Company has seen in the animal model - new hair growth, and the thickness of new and existing hair. The study is in progress, but the Company has reviewed data from the scheduled 12 week time point and is pleased with the results to date.

"Histogen's clinical trial was designed to assess the safety of its product over a five month period," commented Dr. Craig Ziering, principal investigator of the study and founder of Ziering Medical. "In addition to seeing no adverse reactions, we were delighted to see more hair, thicker hair shafts, and what appears to be the growth of completely new hair follicles in the areas that received the ReGenica treatment."

ReGenica is a proprietary liquid formula created by the culturing of newborn fibroblasts in an embryonic-like environment, and then harvesting the naturally secreted embryonic wnt proteins, growth factors, and other synergistic bioproducts that are produced. It is the first naturally stabilized and bioactive formulation of wnt proteins and natural cofactors, which are thought to act in the formation of new hair follicles.

"Wnt signaling has been shown to be responsible for initiating epidermal stem cells to form new hair follicles in mice, and is also important in maintaining the hair inducing activity from existing follicles," said Frank Zeigler, General Manager at Histogen. "We are excited to be the first group to show these effects in a clinical setting using human WNT proteins."

Histogen began this outside-U.S. study of ReGenica for hair regrowth in November, with the goal of more rapidly obtaining human safety data which will allow the Company to progress with product development. The trial is currently ongoing, and Histogen expects to release full results from this first clinical study in the first half of 2009.

Dr. Gail Naughton has spent more than 15 years extensively researching the tissue engineering process, and holds more than 90 patents in the field. Dr. Naughton founded Histogen in 2007, and currently serves as Chief Executive Officer and Chairman of the Board for the Company, in addition to her position as Dean of the College of Business at San Diego State University.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. For more information, please visit http://www.histogeninc.com.

###

Read the full story at http://www.prweb.com/releases/Histogen/Hairtrial/prweb2069524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. David Bagley Joins Histogen as President
2. Histogen Featured on Economic Report Television Series
3. Histogen Welcomes Dr. Hyma Gollamudi as Chief Business Officer
4. Histogen Announces Start of Hair Regrowth Clinical Evaluation
5. Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine
6. Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board
7. Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market
8. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
9. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
10. Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Histogen to Present Preliminary Hair Regrowth Clinical Results at Stem Cell Summit
(Date:6/15/2017)... ... June 15, 2017 , ... DuPont Industrial ... will be speaking at Bloomberg’s 2017 Sustainable Business Summit: Seattle this ... and sustainability officials on a panel titled “Developing a Corporate Renewables Strategy.” ...
(Date:6/14/2017)... ... June 14, 2017 , ... The Thailand Board ... announces that they’re co-hosting a delegation from Thailand at BIO 2017 in San ... industry gathering in the world, regroups more than 1,100 biotech companies, academic institutions, ...
(Date:6/14/2017)... ... 14, 2017 , ... Cynvenio Biosystems, Inc. a ... distribution agreements for Cynvenio’s ClearID line of blood tests that support targeted treatment selection ... ClearID available immediately in Israel, Greece, Argentina, and South Korea. , ...
(Date:6/14/2017)... ... June 14, 2017 , ... ... 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) ... diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):